Multi-target drug discovery for rheumatoid arthritis: a comprehensive computational approach using bioactive...

Area of Science:

• Biochemistry and Molecular Biology
• Immunology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) is a prevalent inflammatory disease with complex pathogenesis involving multiple signaling pathways.
• Current treatments targeting single pathways in RA often yield insufficient patient improvement.
• Identifying novel therapeutic strategies, particularly those with multi-target capabilities, is crucial for effective RA management.

Purpose of the Study:

• To identify safe, natural product-derived drug candidates for rheumatoid arthritis (RA) using in silico screening.
• To evaluate the efficacy of these candidates against multiple key protein targets implicated in RA pathogenesis.
• To introduce novel compounds with potential for multi-targeted inhibition in RA treatment.

Main Methods:

• In silico virtual screening of natural products against selected RA protein targets.
• Molecular docking simulations to assess binding affinity and stability.
• Molecular dynamics simulations to analyze the dynamic behavior of drug-target interactions.

Main Results:

• Rutaecarpine, Hecogenin, and Angustine were identified as potent inhibitors of Tyrosine Kinase 2 (TYK2), Interleukin-6 (IL-6), and CD20.
• Vomicine demonstrated significant inhibition against TYK2 and IL-6, but not CD20.
• These natural compounds exhibited high affinity and stability in their interactions with the targeted proteins.

Conclusions:

• Rutaecarpine, Hecogenin, and Angustine represent promising multi-target drug candidates for rheumatoid arthritis.
• Vomicine is a potential candidate for targeting TYK2 and IL-6 pathways in RA.
• Further experimental validation is warranted to confirm the therapeutic potential of these natural compounds in treating RA.